Related Experiment Videos
Mapping the arrestin-receptor interface. Structural elements responsible for receptor specificity of arrestin
Sergey A Vishnivetskiy1, M Marlene Hosey, Jeffrey L Benovic
1Department of Pharmacology, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA.
The Journal of Biological Chemistry
|October 8, 2003
Summary
Arrestins bind to activated G protein-coupled receptors, influencing signaling. Specific regions within visual arrestin and arrestin2 determine their unique receptor preferences.
Area of Science:
- Molecular and Cellular Biology
- Biochemistry
- Pharmacology
Background:
- Arrestins are key regulators of G protein-coupled receptor (GPCR) signaling.
- Arrestin binding to phosphorylated GPCRs terminates G protein activation and initiates biased signaling.
- Understanding arrestin-GPCR interactions is crucial for drug discovery targeting GPCR pathways.
Purpose of the Study:
- To identify the specific structural elements responsible for the receptor specificity of visual arrestin and arrestin2.
- To elucidate the molecular mechanisms underlying arrestin-GPCR recognition.
Main Methods:
- Comparative analysis of crystal structures of arrestins and rhodopsin.
- Mutagenesis studies and peptide inhibition assays.
- Construction and functional characterization of visual arrestin/arrestin2 chimeras for binding assays.
Main Results:
- Specific regions in the N-domain (residues 49-90) and C-domain (residues 237-268) of visual arrestin and arrestin2 were identified as critical for receptor preference.
- These regions differ by only 35 amino acids, with 22 nonconservative substitutions.
- Simultaneous exchange of these two elements between visual arrestin and arrestin2 completely reversed their receptor specificity.
Conclusions:
- The identified N-domain and C-domain elements are necessary and sufficient for determining arrestin receptor specificity.
- These findings provide a molecular basis for understanding how arrestins achieve selectivity for distinct GPCRs.
- This knowledge can inform the design of novel therapeutics modulating GPCR signaling through arrestin pathways.